The apoE-mimetic peptide, COG1410, improves functional recovery in a murine model of intracerebral hemorrhage.

Published

Journal Article

Apolipoprotein E has previously been demonstrated to modulate acute brain injury responses, and administration of COG1410, an apoE-mimetic peptide derived from the receptor-binding region of apoE, improves outcome in preclinical models of acute neurological injury. In the current study, we sought to establish the optimal dose and timing of peptide administration associated with improved functional outcome in a murine model of intracerebral hemorrhage (ICH).Ten to twelve-week-old C57/BL6 male mice were injured by collagenase-induced ICH and randomly selected to receive either vehicle or one of four doses of COG1410 (0.5, 1, 2, or 4 mg/kg) via tail vein injection at 30 min after injury and then daily for 5 days. The injured mice were euthanized at various time points to assess inflammatory mediators, cerebral edema, and hematoma volume. Over the first 5 days following injury, vestibulomotor function was tested via Rotorod (RR) latency. After an optimal dose was demonstrated, a final cohort of animals was injured with ICH and randomly assigned to receive the first dose of COG1410 or vehicle at increasingly longer treatment initiation times after injury. The mice were then assessed for functional deficit via RR testing over the first 5 days following injury.The mice receiving 2 mg/kg of COG1410 after injury demonstrated reduced functional deficit, decreased brain concentrations of inflammatory proteins, and less cerebral edema, although hematoma volume did not vary. The improved RR performance was maintained when peptide administration was delayed for up to 2 h after ICH.COG1410 administered at a dose of 2 mg/kg within 2 h after injury improves functional recovery in a murine model of ICH.

Full Text

Duke Authors

Cited Authors

  • Laskowitz, DT; Lei, B; Dawson, HN; Wang, H; Bellows, ST; Christensen, DJ; Vitek, MP; James, ML

Published Date

  • April 2012

Published In

Volume / Issue

  • 16 / 2

Start / End Page

  • 316 - 326

PubMed ID

  • 21989844

Pubmed Central ID

  • 21989844

Electronic International Standard Serial Number (EISSN)

  • 1556-0961

International Standard Serial Number (ISSN)

  • 1541-6933

Digital Object Identifier (DOI)

  • 10.1007/s12028-011-9641-5

Language

  • eng